Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05105789 · ClinicalTrials.gov registry record · NA

Safe and Healthy Schools

A NA study of COVID-19 and SARS CoV 2 Infection, sponsored by University of Wisconsin, Madison.

Completed
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT05105789 is a NA study of COVID-19 and SARS CoV 2 Infection that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 100 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05105789, a NA study of COVID-19 and SARS CoV 2 Infection, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This study will target Madison Metropolitan School District (MMSD) school children ages 4-19 and staff who have not had a previous positive COVID-19 test within the past 3 months. It will enroll children and adults for 1-3 days to explore whether serial "at-home" BinaxNOW testing is feasible and non-inferior to "at school" single PCR testing for the evaluation of symptomatic individuals with a negative initial BinaxNOW. It will also explore whether lollipop swabs are more acceptable and perform as well as nasal swabs with polymerase chain reaction (PCR) testing.

Interventions

  • DIAGNOSTIC_TEST BinaxNOW Test
  • DIAGNOSTIC_TEST "Lollipop" swab

Study Locations (1)

Wisconsin

  • Community Locations - Madison

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-10-11
Est. Completion 2023-05-21
Phase NA

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT05105789

The ClinicalTrials.gov registry entry for NCT05105789 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which BinaxNOW Test is the first listed.

NCT05105789 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05105789 about?

NCT05105789 is a clinical study titled "Safe and Healthy Schools". This study will target Madison Metropolitan School District (MMSD) school children ages 4-19 and staff who have not had a previous positive COVID-19 test within the past 3 months. It will enroll children and adults for 1-3 days to explore whether serial "at-home" BinaxNOW testing is feasible and non...

What is the current status of trial NCT05105789?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2021-10-11. Estimated completion is 2023-05-21.

What conditions does trial NCT05105789 study?

This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection.

What interventions are being tested in trial NCT05105789?

The interventions under investigation include: BinaxNOW Test (DIAGNOSTIC_TEST), "Lollipop" swab (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05105789?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05105789 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.